Samuel A Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J Montero, Corey Lipchik, Melanie Finnigan, Rachel C Jankowitz, Mohamad A Salkeni, Sai K Maley, Shannon L Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J Nagy, Carmen J Allegra, Kelly Vehec, Norman Wolmark, Peter C Lucas, Ashok Srinivasan, Katherine L Pogue-Geile
BACKGROUND: We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer patients. Patients with ERBB2 amplification in ctDNA had deeper and more durable responses. This study extends these observations with in-depth analysis of molecular markers and mechanisms of resistance in additional patients. METHODS: Forty-nine HER2-positive patients (determined locally) who progressed on-treatment with trastuzumab + pertuzumab were enrolled in this phase Ib/II study...
April 22, 2024: Breast Cancer Research: BCR